NDA 213976 · Takeda Pharms USA
Eohilia
Budesonide · Oral · Corticosteroid
Breakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: May 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Feb 9, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
592
206 Phase 3, 32 recruiting
FAERS reports
40,872
31,603 serious, 3,109 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 3, 2025.
EOHILIA ™ is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). Limitations of Use EOHILIA has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks [see Dosage and Administration (2.1) , Clinical Studies (14) ]. EOHILIA is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). ( 1 ) Limitations of Use EOHILIA has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks. ( 1 , 2.1 , 14 )
Mechanism: Budesonide is an anti-inflammatory corticosteroid and has a high glucocorticoid effect and a weak mineralocorticoid effect, and the affinity of budesonide to glucocorticoid receptors, which reflects the intrinsic potency of the drug, is about 200-fold that of cortisol and 15-fold that of prednisolone. The precise mechanism of corticosteroid actions on inflammation in EoE is not known. Inflammation is an important component in the pathogenesis of EoE. Corticosteroids have a wide range of inhibitory activities against multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 9, 2024 Original approval · Type 3 - New Dosage Form · priority review Breakthrough therapyOrphanLabelLetterReview
1 products under this application
- EOHILIA · BUDESONIDE 2MG/10ML · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Budesonide" as an intervention, any sponsor and status, largest first.
- A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and AdolescentsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01444430 · 12,460 participants · Start Dec 2011 · Primary completion Oct 2015
Drug: Symbicort pMDI; budesonide pMDI · For: Asthma
Sites: Birmingham, Alabama; Huntsville, Alabama; Anchorage, Alaska · 340 sites in all
- Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02465567 · 8,588 participants · Start Jun 30, 2015 · Primary completion Jul 26, 2019
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg and 2 more · For: COPD
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 741 sites in all
- Local Phase 4 Pan-European SMART StudyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00463866 · 8,424 participants · Start Mar 2007
Drug: Budesonide/formoterol · For: Asthma
Sites: Aalst, Belgium; Aarschot, Belgium; Aatrijken, Belgium · 817 sites in all
- Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild SymptomsPivotal-lookingStatus unknown
CardresearchAcademic, hospital or other
NCT04727424 · 7,819 participants (planned) · Start Jan 19, 2021 · Primary completion Jun 1, 2024
Drug: Budesonide Powder; Fluoxetine 20 MG and 1 more · For: Covid19; SARS-Associated Coronavirus
Sites: Belo Horizonte, Brazil; Betim, Brazil; Brumadinho, Brazil · 12 sites in all
- Inhaled Steroid Treatment as Regular Therapy in Early AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00641914 · 6,800 participants (planned) · Start Oct 1996 · Primary completion Feb 2003
Drug: budesonide; Placebo · For: Asthma
- A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06283966 · 5,250 participants (planned) · Start Feb 21, 2024 · Primary completion Dec 3, 2027
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Athens, Alabama; Cullman, Alabama; Fairhope, Alabama · 922 sites in all
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02224157 · 4,215 participants · Start Nov 28, 2014 · Primary completion Aug 16, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; budesonode bid + terbutaline 'as needed' · For: Asthma
Sites: Sydney, Australia; Botucatu, Brazil; Florianópolis, Brazil · 340 sites in all
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02149199 · 3,850 participants · Start Jul 7, 2014 · Primary completion Aug 2, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; terbutaline 'as needed' + placebo budesonide bid and 1 more · For: Asthma
Sites: Bedford Park, Australia; Concord, Australia; Maroubra, Australia · 255 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,932
- dyspnoea4,578
- off label use4,454
- asthma3,631
- fatigue2,606
- condition aggravated2,494
- headache2,444
- diarrhoea2,391
- cough2,247
- pneumonia2,247
- nausea2,115
- wheezing2,025
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 138 |
| 2005 | 220 |
| 2006 | 195 |
| 2007 | 197 |
| 2008 | 282 |
| 2009 | 292 |
| 2010 | 320 |
| 2011 | 533 |
| 2012 | 736 |
| 2013 | 782 |
| 2014 | 978 |
| 2015 | 1,346 |
| 2016 | 1,591 |
| 2017 | 1,682 |
| 2018 | 2,259 |
| 2019 | 2,940 |
| 2020 | 3,524 |
| 2021 | 3,719 |
| 2022 | 4,003 |
| 2023 | 3,975 |
| 2024 | 4,199 |
| 2025 | 4,082 |
| 2026 | 2,879 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Eohilia (Budesonide)
2024 spending
$1.6M
Beneficiaries
440
776 claims
Per beneficiary
$3,531
$3.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,553,442 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.
O'Byrne PM, FitzGerald JM, Bateman ED, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma.
Bateman ED, Reddel HK, O'Byrne PM, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Beasley R, Holliday M, Reddel HK, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Budesonide nasal irrigation for chronic rhinosinusitis: a meta-analysis of therapeutic outcomes and safety profile.
Magboul N, Alharbi AF, Alqutub AT, et al. · Rhinology 2025 · Meta-Analysis, Systematic Review
- Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial.
Chipps BE, Israel E, Beasley R, et al. · Chest 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.